EU CHMP recommends refusal of application for Adlumiz (anamorelin) for anorexia, cachexia or unintended weight loss in patients with non-small cell lung cancer -Helsinn Birex Pharmaceuticals
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest